Oncopeptides AB (publ)
ONPPF
Other OTC0.27
USD
- -
- -
ISIN
SE0009414576
Return %
Stock
S&P500
1Y
- -
26.53
3Y
-68.82
76.60
5Y
-98.63
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Sofia Heigis
- Full Time Employees
- 80
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Vastra Tradgardsgatan 15 Stockholm Sweden 111 53
- IPO Date
- Dec 16, 2020
- Website
- oncopeptides.com
- Similar Companies
- Business
- Oncopeptides AB (publ) is a Swedish biotechnology company specializing in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological cancers. The company's core products and services center around its proprietary Peptide Drug Conjugate (PDC) platform and the newly introduced SPiKE platform. The PDC technology enables the development of compounds that selectively deliver cytotoxic agents into cancer cells, with the flagship product Pepaxti (melphalan flufenamide) approved and commercialized in Europe for the treatment of relapsed or refractory multiple myeloma. Beyond Pepaxti, Oncopeptides is advancing multiple drug candidates based on its PDC and SPiKE platforms, aiming to innovate further in hematologic malignancies and immune system engagement in cancer therapy. Oncopeptides operates mainly in Europe with active commercialization in Germany, Italy, Spain, and Austria, and has expanded its reach through strategic partnerships to South Korea, the Middle East, Africa, and Eurasia. The company recently announced significant sales growth, especially propelled by stronger-than-expected organic sales in Germany and accelerated market access in Spain and Italy. In 2025, Oncopeptides formed a partnership with SD Pharma to enhance Pepaxti's distribution across Spanish hospital channels and expanded its collaboration for commercialization in Sub-Saharan Africa and Eurasia, consolidating its global footprint. The company is also in advanced partnership discussions for Japan and has ongoing regulatory dialogues with the U.S. FDA regarding its next-generation PDC pipeline molecule OPD5. Founded in 2000 and headquartered in Stockholm, Sweden, Oncopeptides employs around 80 personnel. The company is listed on Nasdaq Stockholm under the ticker ONCO and operates in the biotechnology/pharmaceutical sector focusing on hematologic cancer therapies. Recent strategic moves include expanding reimbursement access in key European markets, enhancing sales momentum, and maintaining a cost base aligned with profitability goals targeted for 2026. Oncopeptides continues to invest in evolving its proprietary platforms and exploring combination therapies to improve treatment durability and efficacy. This comprehensive approach combining innovative drug development, market expansion, and strategic partnerships underscores Oncopeptides’ focus on addressing unmet needs in difficult-to-treat cancers with advanced targeted therapies.
Oncopeptides AB (publ) (ONPPF) Q4 2025 Sales/Trading Call Transcript
Oncopeptides AB (publ) (ONPPF) Q3 2025 Earnings Call Transcript
Oncopeptides presents new data from OCEAN and PORT study - abstracts online
After Second Look Oncopeptides' Melflufen Wins Head-To-Head Myeloma Trial, But Difference In OS Triggers FDA Hold